S17 - Movement Disorders: Ataxia and the Cerebellum

Event Time: Monday April 24, 2017 3:30 pm to 5:30 pm
Topic(s): Movement Disorders
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 ATXN2 antisense therapy improves SCA2 mouse motor and Purkinje cell electrophysiological phenotypes. Daniel Scoles, PhD
Disclosure:
Dr. Scoles has nothing to disclose.

3:42 PM 002 Fragile X Gray Zone Alleles are associated with Better Global Motor Function in an Elderly Community Population Deborah Hall, MD, PhD, FAAN
Disclosure:
Dr. Hall has received personal compensation in an editorial capacity from the American Academy of Neurology. Dr. Hall has received research support from Neurocrine, Pfizer, and Abbvie.

3:54 PM 003 RT001 First-in Human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich’s Ataxia Theresa Zesiewicz, MD, FAAN
Disclosure:
Dr. Zesiewicz has nothing to disclose.

4:06 PM 004 Exome Sequencing Offers a Comprehensive Genetic Evaluation and High Diagnostic Rate for Ataxia-related Disorders Francisca Millan
Disclosure:
Dr. Millan has received personal compensation for activities with GeneDx as an employee.

4:18 PM 005 EPI-743 (Alpha-tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich's Ataxia Theresa Zesiewicz
Disclosure:
Dr. Zesiewicz has nothing to disclose.

4:30 PM 006 Cerebellar Pathology in Early Onset and Late Onset Essential Tremor Sheng-Han Kuo, MD
Disclosure:
Dr. Kuo has nothing to disclose.

4:42 PM 007 Structure-Phenotype relationships in ATP1A3 (Na,K-ATPase) diseases Kathleen J Sweadner
Disclosure:
Dr. Sweadner has nothing to disclose.

4:54 PM 008 In vivo drug discovery for progressive supranuclear palsy using a novel zebrafish model Qing Bai
Disclosure:
Dr. Burton has nothing to disclose.

Register Now

Related Courses